spacer
home > epc > autumn 2003 > new approaches to developing cancer drugs
PUBLICATIONS
European Pharmaceutical Contractor

New Approaches to Developing Cancer Drugs

The latest statistics make alarming reading: in the developed world one in three people will suffer from cancer and one in four will die from the disease. Due to an ageing population the worldwide incidence of cancer is predicted to double from 10 to 20 million by 2020 (WHO). Traditional approaches to cancer treatment rely on a combination of surgery, radiotherapy and chemotherapy. Current cancer drugs, which are mostly lethal for cells (cytotoxic), either affect DNA synthesis and the process of cell division or they react chemically with DNA to cause chromosomal damage.

These drugs have major limitations as they damage all proliferating cells and therefore produce considerable side effects. Drug resistance is another serious problem. Hence there is a major unmet need for more systematic but innovative and effective therapies for cancer treatment, especially for targeting early stages of the disease or later stage metastatic disease.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Gijsbertus J Pronk PhD, Senior Director, US Business Development at atugen AG

Gijsbertus J Pronk, PhD, is Senior Director in charge of US business development for atugen AG, Germany. Bert joined atugen, USA Inc in 2000 as Director of Research having formerly been Senior Scientist for Target Development with Chiron Corporation. Previously he held various research posts including a post-doctoral assignment in the laboratory of Dr Lewis T Williams at the Cardio-Vascular Research Institute (CVRI) at UC-San Francisco, where he studied programmed cell death (apoptosis).

spacer
Gijsbertus J Pronk
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm Expands Relationship With Novan On Formulation Science

MedPharm Ltd, a leader in topical and transdermal drug delivery, has expanded its relationship with the NASDAQ listed biopharmaceutical company Novan Inc. MedPharm has previously supported Novan by testing the companyís unique formulations using its proprietary in vitro models to optimise Novanís formulations and de-risk product development.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement